Key Takeaways GILD's ARTISTRY-2 showed once-daily BIC/LEN was non-inferior to Biktarvy at week 48.GILD randomized virologically suppressed patients 2:1 to switch to BIC/LEN or stay on Biktarvy.GILD plans regulatory filings combining phase III results from ARTISTRY-1 and ARTISTRY-2.Gilead Sciences, Inc. (GILD) announced that the investigational single-tablet regimen of bictegravir and lenacapavir for the treatment of HIV met the primary endpoint in the late-stage ARTISTRY-2 study.ARTISTRY-2 is a multicenter, ...

Gilead Sciences (NasdaqGS:GILD) FY 2025 Conference December 02, 2025 11:15 AM ET Company ParticipantsNone - Company RepresentativeConference Call ParticipantsNone - AnalystNoneUsed in about 45% of HIV prevention patients today. It's a once-daily pill with two medicines. The daily orals work really well. The challenge is that people that don't have HIV do not take the pills on a daily basis, so you don't get the benefit that you would get if people stayed on the pills every day. It's really challenging. The ...